Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
about
Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gammaEffect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome.Sources of evidence for systematic reviews of interventions in diabetes.Estimating the potential annual welfare impact of innovative drugs in use in Switzerland.Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyComparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological studyEconomic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.Clinical effect of Metformin in children and adolescents with type 2 diabetes mellitus: a systematic review and meta-analysis.Pioglitazone in the treatment of type 2 diabetes: safety and efficacy reviewJicama (Pachyrhizus erosus) extract increases insulin sensitivity and regulates hepatic glucose in C57BL/Ksj-db/db mice.Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.The metabolic syndrome in hypertension: diagnostic and therapeutic implications.Effects of thiazolidinediones on blood pressure.Frienemies of infection: A chronic case of host nuclear receptors acting as cohorts or combatants of infection.PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
P2860
Q28505209-CB6DA8D3-B74E-4BF5-AE87-B3E622C0B532Q30472847-BF74B74F-4202-41E3-AD82-37C0649013DEQ33223698-B2516358-5C61-45AD-8265-AFF4DE875A3FQ33658487-DBDB4E8B-A0C8-41DC-AFF4-3F3137EAF9BFQ34449858-6023E326-5836-4491-BE4A-9E5B63305CCCQ34567058-393ADD24-0047-4451-AC29-B1E29B8C60DAQ36112385-F9CA0AC6-9016-48A3-ADBD-6D14C12B82FDQ36134357-F07BACBE-8C15-4799-9A8E-4224D3EE70AFQ36139056-B7526268-4610-4C4F-A828-235C611F4AD8Q36444545-A62C0BC7-2C01-4A28-9981-D84FBFEA9239Q36519207-C242E81A-3602-4172-AF82-D117D6076365Q36577073-30FCA331-CEBB-42AA-84AC-7995A310E90DQ36905141-A89506DA-4B74-4872-AC8B-5009C6F5078BQ36905154-50CD3EA4-82B9-482B-BF94-6D526C02840FQ38263962-0CB6A899-7840-4B80-91AD-6BBB88262CF6Q46252518-597EF2EB-9348-44E9-AEEF-F63EB10DC07FQ47173372-6EAEC1AD-7FF3-4CD6-A07B-7E8502F48C22
P2860
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical effectiveness and cos ...... eview and economic evaluation.
@ast
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
type
label
Clinical effectiveness and cos ...... eview and economic evaluation.
@ast
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
prefLabel
Clinical effectiveness and cos ...... eview and economic evaluation.
@ast
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
P2093
P356
P1476
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
P2093
C Beverley
C Czoski-Murray
J Chilcott
M A Psyllaki
P304
iii, ix-x, 1-91
P356
10.3310/HTA8130
P577
2004-04-01T00:00:00Z